[
1. Egbuna OI, Brown EM. Hypercalcaemic and hypocalcaemic conditions due to calcium-sensing receptor mutations. Best Pract Res Clin Rheumatol. 2008, 22, 129-148.
]Search in Google Scholar
[
2. Springhurst FR, Demay MB, Kronenberg HM. Hormones and disorders of mineral metabolism. In: Williams Textbook of Endocrinology. Vol. 1. Kronenberg HM.Melmed S,Polonsky, KS., Larsen PR (editors), Saunders Elsevier, 2008, 1203-1268.
]Search in Google Scholar
[
3. Silva BC, Costa AG, Cusano NE, et al. Catabolic and anabolic actions of parathyroid hormone on the skeleton. J Endocrinol Invest, 2011, 34, 801-810.
]Search in Google Scholar
[
4. Balani DH, Ono N, Kronenberg HM. Parathyroid hormone regulates fates of murine osteoblast precursors in vivo. J Clin Invest, 2017, 127, 3327-38.10.1172/JCI91699566955528758904
]Search in Google Scholar
[
5. Fan Y, Hanai JI, Le PT, et al. Parathyroid hormone directs bone marrow mesenchymal cell fate. Cell Metab, 2017; 25, 661-72.10.1016/j.cmet.2017.01.001534292528162969
]Search in Google Scholar
[
6. Ishizuya T, Yokose S, Hori M, et al. Parathyroid hormone exerts disparate effects on osteoblast differentiation depending on exposure time in rat osteoblastic cells. J Clin Invest, 1997, 99 (12), 2961-70.10.1172/JCI1194915081489185520
]Search in Google Scholar
[
7. Bellido T, Ali AA, Plotkin LI, et al. Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism. J Biol Chem, 2003, 278(50), 50259-72.10.1074/jbc.M30744420014523023
]Search in Google Scholar
[
8. Schnoke M, Midura SB, Midura RJ. Parathyroid hormone suppresses osteoblast apoptosis by augmenting DNA repair. Bone, 2009, 45(3), 590-602.10.1016/j.bone.2009.05.006275283619450716
]Search in Google Scholar
[
9. Aslan D, Andersen MD, Gede LB, et al. Mechanisms for the bone anabolic effect of parathyroid hormone treatment in humans. Scand J Clin Lab Invest, 2012, 72(1), 14-22.10.3109/00365513.2011.62463122085136
]Search in Google Scholar
[
10. Bodine PV, Komm BS. Wnt signaling and osteoblastogenesis. Rev Endocr Metab Disord, 2006, 7(1-2), 33-39.10.1007/s11154-006-9002-416960757
]Search in Google Scholar
[
11. Almeida M, Han L, Bellido T, et al. Wnt proteins prevent apoptosis of both uncommitted osteoblast progenitors and differentiated osteoblasts by beta-catenin-dependent and-independent signaling cascades involving Src/ERK and phosphatidylinositol 3-kinase/AKT. J Biol Chem, 2005, 280(50), 41342-51.10.1074/jbc.M50216820016251184
]Search in Google Scholar
[
12. Bodine PV, Billiard J, Moran RA, at al. The Wnt antagonist secreted frizzled-related protein-1 controls osteoblast and osteocyte apoptosis. J Cell Biochem, 2005, 96(6), 1212-30.10.1002/jcb.2059916149051
]Search in Google Scholar
[
13. Glass DA 2nd, Bialek P, Ahn JD, et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Developmental cell 2005, 8, 751-764.10.1016/j.devcel.2005.02.01715866165
]Search in Google Scholar
[
14. Kulkarni NH, Halladay DL, Miles RR, et al. Effects of parathyroid hormone on Wnt signaling pathway in bone. J Cell Biochem, 2005, 95(6), 1178-90.10.1002/jcb.20506
]Search in Google Scholar
[
15. Bellido T, Ali AA, Gubrij I, et al. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology, 2005, 146(11), 4577-8310.1210/en.2005-0239
]Search in Google Scholar
[
16. Qin L, Qiu P, Wang L, et al. Gene expression profiles and transcription factors involved in parathyroid hormone signaling in osteoblasts revealed by microarray and bioinformatics. J Biol Chem, 2003, 278, 19723-31.10.1074/jbc.M212226200
]Search in Google Scholar
[
17. Kim JH, Kim N. Signaling Pathways in Osteoclast Differentiation. Chonnam Med J, 2016, 52(1), 12-17.10.4068/cmj.2016.52.1.12
]Search in Google Scholar
[
18. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell, 1997, 89, 309-319.10.1016/S0092-8674(00)80209-3
]Search in Google Scholar
[
19. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology, 2001, 142, 5050-55.10.1210/endo.142.12.853611713196
]Search in Google Scholar
[
20. Kearns AE, Khosla S, Kostenuik PJ. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev, 2008, 29, 155-192.10.1210/er.2007-0014252884618057140
]Search in Google Scholar
[
21. Ma YL, Cain RL, Halladay DL, et al. Catabolic effects of continuous human PTH (1-38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology, 2001, 142, 4047-54.10.1210/endo.142.9.835611517184
]Search in Google Scholar
[
22. Huang JC, Sakata T, Pfleger LL, et al. PTH differentially regulates expression of RANKL and OPG. J Bone Miner Res, 2004,19, 235-244.10.1359/JBMR.030122614969393
]Search in Google Scholar
[
23. Keller H, Kneissel M. SOST is a target gene for PTH in bone. Bone, 2005, 37, 148-58.10.1016/j.bone.2005.03.01815946907
]Search in Google Scholar
[
24. Bonewald LF. The amazing osteocyte. J Bone Miner Res, 2011, 26, 229-38.10.1002/jbmr.320317934521254230
]Search in Google Scholar
[
25. O’Brien CA, Nakashima T, Takayanagi H. Osteocyte control of osteoclastogenesis. Bone, 2013, 54, 258-63.10.1016/j.bone.2012.08.121353891522939943
]Search in Google Scholar
[
26. van Bezooijen RL, ten Dijke P, Papapoulos SE, et al. SOST/sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor Rev, 2005, 16, 319-27.10.1016/j.cytogfr.2005.02.00515869900
]Search in Google Scholar
[
27. Ben-awadh AN, Delgado-Calle J, Tu X, et al. Parathyroid hormone receptor signaling induces bone resorption in the adult skeleton by directly regulating the RANKL gene in osteocytes. Endocrinology, 2014, 155, 2797-809.10.1210/en.2014-1046409800324877630
]Search in Google Scholar
[
28. Hory BG, Roussanne MC, Rostand S, et al. Absence of response to human parathyroid hormone in athymic mice grafted with human parathyroid adenoma, hyperplasia or parathyroid cells maintained in culture. J Endocrinol Invest, 2000, 23(5), 273-9.10.1007/BF0334372310882144
]Search in Google Scholar
[
29. Gao Y, Wu X, Terauchi M, et al. T cells potentiate PTH-induced cortical bone loss through CD40L signaling. Cell Metab, 2008, 8(2), 132-45.10.1016/j.cmet.2008.07.001256984318680714
]Search in Google Scholar
[
30. Pacifici R. T cells: critical bone regulators in health and disease. Bone, 2010, 47, 461-471.10.1016/j.bone.2010.04.611292625820452473
]Search in Google Scholar
[
31. Terauchi M, Li JY, Bedi B, et al. T lymphocytes amplify the anabolic activity of parathyroid hormone through Wnt10b signaling. Cell Metab, 2009, 10(3), 229-240.10.1016/j.cmet.2009.07.010275185519723499
]Search in Google Scholar
[
32. D’Amelio P, Sassi F, Buondonno I, et al. Treatment with intermittent PTH increases Wnt10b production by T cells in osteoporotic patients. Osteoporos Int., 2015, 26(12), 2785-91.10.1007/s00198-015-3189-826068297
]Search in Google Scholar
[
33. Tawfeek H, Bedi B, Li JY, et al. Disruption of PTH receptor 1 in T cells protects against PTH-induced bone loss. PLoS One, 2010, 5(8), e12290.10.1371/journal.pone.0012290292490020808842
]Search in Google Scholar
[
34. Li JY, D’Amelio P, Robinson J, et al. IL-17A Is Increased in Humans with Primary Hyperparathyroidism and Mediates PTH-Induced Bone Loss in Mice. Cell Metab, 2015, 22(5), 799-810.10.1016/j.cmet.2015.09.012463503426456334
]Search in Google Scholar
[
35. Tawfeek H, Bedi B, Li JY, et al. Disruption of PTH Receptor 1 in T cells protects against PTH-induced bone loss. PLoS One, 2010, 5, e12290.10.1371/journal.pone.0012290292490020808842
]Search in Google Scholar
[
36. Wermers RA, Khosla S, Atkinson EJ, et al. Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993-2001: an update on the changing epidemiology of the disease. J. Bone Miner Res, 2006, 21, 171-7.10.1359/JBMR.05091016355286
]Search in Google Scholar
[
37. Lee JH, Chung SM, Kim HS. Osteitis fibrosa cystica mistaken for malignant disease. Clin Exp Otorhinolaryngol, 2013, 6, 110-3.10.3342/ceo.2013.6.2.110368706023799171
]Search in Google Scholar
[
38. Bandeira F, Cusano NE, Silva BC, et al. Bone disease in primary hyperparathyroidism. Arq Bras Endocrinol Metabol, 2014, 58, 553-61.10.1590/0004-2730000003381431535725166047
]Search in Google Scholar
[
39. Marcocci C, Cianferotti L, Cetani F. Bone disease in primary hyperparathyrodism. Ther Adv Musculoskelet Dis, 2012, 4, 357-68.10.1177/1759720X12441869345861523024712
]Search in Google Scholar
[
40. Chew FS, Huang-Hellinger F. Brown tumor. Am. J. Roentgen-ol, 1993, 160, 752-752.10.2214/ajr.160.4.84566578456657
]Search in Google Scholar
[
41. Van der Woude HJ, Smithuis R. Bone tumor – systematic approach and differential diagnosis. Radiologyassistant (2010).
]Search in Google Scholar
[
42. Selvi F, Cakarer S, Tanakol R, et al. Brown tumor of the maxilla and mandible: a rare complication of tertiary hyperparathyroidism. Dentomaxillofacial Radiol, 2009, 38, 53-58.10.1259/dmfr/8169458319114425
]Search in Google Scholar
[
43. Silverberg SJ, Shane E, de la Cruz L, et al. Skeletal disease in primary hyperparathyroidism. J Bone Miner Res, 1989, 4, 283-91.10.1002/jbmr.56500403022763869
]Search in Google Scholar
[
44. Parisien M, Cosman F, Mellish RW, et al. Bone structure in postmenopausal hyperparathyroid, osteoporotic, and normal women. J Bone Miner Res, 1995, 10, 1393-9.10.1002/jbmr.56501009177502712
]Search in Google Scholar
[
45. Lewiecki EM, Miller PD. Skeletal effects of primary hyper-parathyroidism: bone mineral density and fracture risk. J Clin Densitom, 2013, 16, 28-32.10.1016/j.jocd.2012.11.013
]Search in Google Scholar
[
46. Rubin MR, Bilezikian JP, McMahon DJ, et al. The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metab, 2008, 93, 3462-70.10.1210/jc.2007-1215
]Search in Google Scholar
[
47. Bilezikian JP, Brandi ML, Eastell R, et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab, 2014, 99, 3561-9.10.1210/jc.2014-1413
]Search in Google Scholar
[
48. Silva BC, Boutroy S, Zhang C, et al. Trabecular bone score (TBS) - a novel method to evaluate bone microarchitectural texture in patients with primary hyperparathyroidism. J Clin Endocrinol Metab, 2013, 98, 1963-70.10.1210/jc.2012-4255
]Search in Google Scholar
[
49. Stein EM, Silva BC, Boutroy S, et al. Primary hyperparathyroidism is associated with abnormal cortical and trabecular microstructure and reduced bone stiffness in postmenopausal women. J Bone Miner Res, 2013, 28, 1029-40.10.1002/jbmr.1841
]Search in Google Scholar
[
50. Makras P, Anastasilakis AD. Bone disease in primary hyper-parathyroidism. Metabolism, 2018, 80, 57-65.10.1016/j.metabol.2017.10.003
]Search in Google Scholar
[
51. Valdemarsson S, Lindergård B, Tibblin S, et al. Increased biochemical markers of bone formation and resorption in primary hyperparathyroidism with special reference to patients with mild disease. J Intern Med, 1998, 243(2), 115-122.10.1046/j.1365-2796.1998.00241.x
]Search in Google Scholar
[
52. Christiansen P, Steiniche T, Brixen K, et al. Primary hyper-parathyroidism: short-term changes in bone remodeling and bone mineral density following parathyroidectomy. Bone, 1999, 25(2), 237-244.10.1016/S8756-3282(99)00150-7
]Search in Google Scholar
[
53. Heaney RP. The basis for the post-parathyroidectomy increase in bone mass. J Bone Miner Res, 2002, 17(2), 154-7.
]Search in Google Scholar
[
54. Silverberg SJ, Shane E, Jacobs TP, et al. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med, 1999, 341(17), 1249-55.10.1056/NEJM19991021341170110528034
]Search in Google Scholar
[
55. Silverberg SJ, Locker FG, Bilezikian JP. Vertebral osteopenia: a new indication for surgery in primary hyperparathyroidism. J Clin Endocrinol Metab, 1996 Nov, 81(11), 4007-12.10.1210/jcem.81.11.89238528923852
]Search in Google Scholar
[
56. Thorsen K, Kristoffersson AO, Lorentzon RP. Changes in bone mass and serum markers of bone metabolism after parathyroidectomy. Surgery, 1997,122(5), 882-887.10.1016/S0039-6060(97)90328-7
]Search in Google Scholar
[
57. Steiniche T, Christiansen P, Vesterby A, et al. Primary hyper-parathyroidism: bone structure, balance, and remodeling before and 3 years after surgical treatment. Bone, 2000, 26(5), 535-543.10.1016/S8756-3282(00)00260-X
]Search in Google Scholar
[
58. Garton M, Martin J, Stewart A, et al. Changes in bone mass and metabolism after surgery for primary hyperparathyroidism. Clin Endocrinol (Oxf), 1995, 42(5), 493-500.10.1111/j.1365-2265.1995.tb02668.x7621568
]Search in Google Scholar
[
59. Alonso S, Ferrero E, Donat M, et al. The usefulness of high preoperative levels of serum type I collagen bone markers for the prediction of changes in bone mineral density after parathyroidectomy. J Endocrinol Invest, 2012, 35, 640-644.
]Search in Google Scholar
[
60. Tamura Y, Araki A, Chiba Y, et al. Remarkable increase in lumbar spine bone mineral density and amelioration in biochemical markers of bone turnover after parathyroidectomy in elderly patients with primary hyperparathyroidism: a 5-year follow-up study. J Bone Miner Metab, 2007, 25(4), 226-231.10.1007/s00774-007-0754-z17593492
]Search in Google Scholar
[
61. Vestergaard P. Current pharmacological options for the management of primary hyperparathyroidism. Drugs, 2006, 66, 2189-2207.10.2165/00003495-200666170-0000417137403
]Search in Google Scholar
[
62. Rossini M, Gatti D, Isaiah G, et al. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyper-parathyroidism. J Bone Min Res, 2001, 16, 113-119.10.1359/jbmr.2001.16.1.11311149474
]Search in Google Scholar
